1. nAMD: Choosing the Best Treatment for your Patient

3. Prevalence of nAMD

4. Currently Available Anti-VEGF Therapies Used to Treat nAMD

5. The Use of Anti-VEGF Regimens

6. 12-Month Mean Visual Acuity Outcomes by Treatment Regimen

7. How Much Has Treatment Evolved Since MARINA and ANCHOR Trials?

8. PRN Method: Benefits and Limitations

9. HARBOR Study Results

10. Dosing Regimens in VIEW 1/2 Through 96 Weeks

11. HARBOR Study: Number of Injections

12. AURA Study

13. AURA Study: Mean Visual Acuity Over 2 Years in Patients Treated With Ranibizumab

14. Undertreatment of Patients

15. LUMINOUS Study

16. Visual Acuity Gains Over 1 Year in Treatment-Naive Patients

17. Visual Acuity Stratified by Injection Frequency and Loading Dose

18. PRN vs Treat and Extend

19. Transition to Treat and Extend

20. Fight Retinal Blindness Registry: Baseline to 7 Years Using Treat and Extend Regimen

21. Consensus on Use of Treatment Approaches

22. Consensus on Use of Treatment Approaches (cont)

23. Management of Bilateral Disease

24. Use of Bilateral Simultaneous Treatment in Practice

25. Patient Compliance

26. Optimal Retreatment Interval

27. Long-Term Studies: Take Home Messages

28. Long-Term Causes of Progressive Vision Loss

29. Managing Poor Responders

30. Concluding Remarks

31. Concluding Remarks (cont)

32. Abbreviations

33. Abbreviations